Ipilimumab联合化疗治疗晚期肺鳞癌的单中心安全性观察

发布时间：2018-04-01 23:11

本文选题：肺鳞癌　切入点：Ipilimumab　出处：《中国癌症杂志》2017年01期

【摘要】：背景与目的:以检查点(checkpiont)为靶点的免疫治疗在实体瘤治疗领域有巨大的应用价值,引发了免疫靶向药物的研究热潮。一项研究结果为ipilimumab联合化疗治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的后续研究提供了依据。该研究统计ipilimumab或安慰剂与紫杉醇和卡铂联合作为一线治疗方案治疗Ⅳ期或复发性、组织学为肺鳞状细胞癌的不良事件(adverse events,AEs),评价ipilimumab联合化疗治疗晚期肺鳞癌的安全性。方法:共入组13例经上海交通大学附属胸科医院收治的ⅣA期或ⅣB期ECOG评分标准均小于等于1的肺鳞癌患者。采用随机对照双盲试验,试验组方案为ipilimumab联合紫杉醇与卡铂,对照组方案为安慰剂联合紫杉醇与卡铂。统计治疗过程中发生的AEs。结果:最常见的AEs主要是1级和2级AEs。Ipilimumab单抗组出现的免疫相关AEs(immune-related AEs,ir AEs)包括Ⅰ级的腹泻及皮肤瘙痒,Ⅱ级的皮疹及皮肤瘙痒和Ⅲ级的垂体炎。结论:Ipilimumab单抗的不良反应轻微,可耐受,可处理。
[Abstract]:Background and purpose: to check point (checkpiont) for immune target therapy has great application value in the treatment of solid tumors, triggering immune targeting drugs. An upsurge of research results of ipilimumab combined with chemotherapy in the treatment of non-small cell lung cancer (non-small cell lung cancer, NSCLC) provides the basis for follow-up study of patients the study of statistical ipilimumab or placebo in combination with paclitaxel and carboplatin as first-line treatment regimen in the treatment of stage IV or recurrent, histological adverse events of lung squamous cell carcinoma (adverse, events, AEs), to evaluate the safety of ipilimumab combined with chemotherapy in treatment of advanced lung squamous cell carcinoma. Methods: a total of 13 cases enrolled by Department of Thoracic Hospital Affiliated to Shanghai Jiaotong University the IV stage A or IV B ECOG standard for evaluation were less than or equal to 1 of lung cancer patients. A randomized controlled double-blind trial scheme of test group of ipilimumab combined with paclitaxel and Carboplatin, control group for placebo plus paclitaxel and carboplatin. Statistical treatment in the process of AEs. results: the most common AEs is the main immune related AEs 1 grade and 2 grade AEs.Ipilimumab monoclonal antibody group appeared (immune-related AEs, IR AEs) including diarrhea and skin itching of grade I, grade II skin rash and pruritus and level III hypophysitis. Conclusion: the adverse reactions of Ipilimumab monoclonal antibody can be tolerated, mild, can handle.

【作者单位】：上海交通大学附属胸科医院呼吸内科;
【分类号】：R734.2

【相似文献】